Circulating osteonectin predicts postural imbalance and cardiac dysfunction in heart failure

Vascular Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 107468 - 107468

Published: Jan. 1, 2025

Language: Английский

---

Irisin Predicts Cardiac Contractile and Postural Dysfunction in Patients with Chronic Heart Failure

Archives of Medical Research, Journal Year: 2025, Volume and Issue: 56(5), P. 103203 - 103203

Published: March 23, 2025

Language: Английский

---

Research Progress on the Treatment of Chronic Obstructive Pulmonary Disease Complicated with Sarcopenia

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(04), P. 2340 - 2350

Published: Jan. 1, 2025

Language: Английский

---

Angiotensin Receptor Blockers Improve Sarcopenia-related Quality of Life by Repairing Intestinal Leak in Patients with Chronic Kidney Disease

SN Comprehensive Clinical Medicine, Journal Year: 2025, Volume and Issue: 7(1)

Published: April 24, 2025

Language: Английский

---

Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England (MET-PREVENT): a double-blind, randomised, placebo-controlled trial

The Lancet Healthy Longevity, Journal Year: 2025, Volume and Issue: unknown, P. 100695 - 100695

Published: March 1, 2025

Metformin has effects on multiple biological systems relevant to ageing and been posited as a candidate therapy for sarcopenia physical frailty. We aimed test the efficacy safety of metformin, geroprotector, improve performance in older people with probable prefrailty or In this double-blind, randomised, parallel-group, placebo-controlled trial (MET-PREVENT), participants aged 65 years 4-m walk speed less than 0·8 m/s sarcopenia, characterised by low handgrip strength (<16 kg women <27 men) five times sit-to-stand time longer 15 s (or inability complete sit-to-stands) were recruited from primary care hospital clinics Gateshead Newcastle, UK. Participants randomly assigned (1:1), via web-based system minimisation ensure balance sex baseline speed, receive either 500 mg oral metformin matching placebo three day 4 months. The outcome was adjusted between-group difference at analysed intention-to-treat population (ie, all treatment) who had data, assessed received least one dose study treatment. This is registered ISRCTN registry, ISRCTN29932357, now complete. Between Aug 1, 2021, Sept 30, 2022, 268 individuals screened inclusion trial, 72 (n=36) (n=36; population). Mean age 80·4 (SD 5·7), 42 (58%) female, 30 (42%) male, 70 (97%) White British. follow-up data (n=34 group n=36 group). months 0·57 0·19) 0·58 (0·24) (adjusted treatment effect 0·001 [95% CI -0·06 0·06]; p=0·96). 108 adverse events occurred 35 (100%) 77 33 (92%) 36 placebo, 12 (34%) admissions versus (8%) group. One death occurred, (one [3%] 35), judged be unrelated did not poorly tolerated population. National Institute Health Care Research Newcastle Biomedical Centre.

Language: Английский

---

Senotherapeutic repurposing of metformin for age-related diseases and their signaling pathways

Molecular Biology Reports, Journal Year: 2025, Volume and Issue: 52(1)

Published: April 22, 2025

Language: Английский

---

Metformin improves skeletal muscle and physical capacity by stabilizing neuromuscular junction in older adults Running title: Metformin improves sarcopenia-related quality of life.

Archives of Gerontology and Geriatrics, Journal Year: 2024, Volume and Issue: 127, P. 105587 - 105587

Published: July 26, 2024

Language: Английский

---

Worldwide burden of antidiabetic drug-induced sarcopenia: An international pharmacovigilance study

Archives of Gerontology and Geriatrics, Journal Year: 2024, Volume and Issue: 129, P. 105656 - 105656

Published: Oct. 11, 2024

Language: Английский

---